Evidence supporting the use of: Phytocannabinoid (unspecified)
For the health condition: Anxiety Disorders

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Phytocannabinoids, particularly cannabidiol (CBD), have garnered scientific interest for their potential in managing anxiety disorders. Several preclinical and clinical studies suggest that CBD exhibits anxiolytic effects, possibly through modulation of the endocannabinoid system and serotoninergic signaling. Evidence from randomized controlled trials is limited but promising: for example, a 2019 study published in The Permanente Journal found that CBD reduced anxiety scores in a majority of participants within the first month of use. Additionally, a 2011 study in Neuropsychopharmacology reported that CBD significantly reduced anxiety in individuals with social anxiety disorder during a simulated public speaking test.

However, clinical evidence remains preliminary. Most studies are small, short-term, or involve healthy volunteers rather than individuals with diagnosed anxiety disorders. There is also considerable variability in dosing, formulation, and phytocannabinoid composition, which complicates interpretation. Importantly, while CBD is the primary phytocannabinoid studied for anxiety, the effects of other cannabinoids (such as THC) are less clear and may actually exacerbate anxiety in some individuals.

In summary, while phytocannabinoids—particularly CBD—are being investigated and used to support anxiety disorders, high-quality, large-scale clinical trials are still needed to confirm efficacy and establish optimal dosing protocols. The current scientific evidence supports a cautious but optimistic outlook, justifying a moderate evidence rating.

More about Phytocannabinoid (unspecified)
More about Anxiety Disorders

Products containing Phytocannabinoid (unspecified)

We currently have no products on Vitabase that contain this ingredient.